NSAID exacerbated respiratory disease, often also named as Widal or Samter's triad, is characterized by recalcitrant and refractory chronic rhinosinusitis with nasal polyps, asthma and intolerance to NSAID. In this review we summarize recent epidemiological, mechanistic and therapeutic evidence with a scope on aspirin desenzitisation. Based on currently available and published data we consider aspirin desenzitisation as therapeutic trial rather than standard care.